Antiserum to prolactin lowers blood pressure (BP) in spontaneously hypertensive rats.
The role of PRL in the development of hypertension in the SHR was examined by administering PRL antiserum to neonatal SHR. On days 2-7 post partum, male SHR were injected with 50 microliters/day of either antiserum to PRL (which chronically lowers plasma PRL), normal rabbit serum (NRS), or 0.9% NaCl. Heart rate, BP, and body weight were measured biweekly on weeks 6-14 of age. Anti-PRL lowered BP vs. NaCl on weeks 6, 8, 12, and 14 (range 7-17 mm Hg lower). NRS animals showed BP differences from the NaCl group only on weeks 6 and 14, with no consistent effect. Heart rates fell during the study in the NaCl and anti-PRL groups but not in the NRS group. Anti-PRL and NRS groups had higher heart rates than did the NaCl group. Body weights did not differ between groups except on week 14, when the NRS group weighed less than the NaCl group. These results suggest that while PRL is involved in BP regulation in the SHR, it is not involved in the pathogenesis of the genetic hypertension seen in the strain. In addition, the results suggest that the serum treatment may have caused heart damage which led to an elevation in the heart rates of the serum-treated groups.
D000818:Animals; D001794:Blood Pressure; D001835:Body Weight; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D007106:Immune Sera / Q000276:immunology; D007116:Immunization, Passive; D008297:Male; D011388:Prolactin / Q000276:immunology*; D011817:Rabbits / Q000276:immunology; D051381:Rats; D011918:Rats, Inbred SHR
D007106:Immune Sera; D011388:Prolactin